Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa treatment

besponsa treatment

Перейти к контенту

Главное меню:

Разное
besponsa treatment
Welcome to BESPONSA® | BESPONSA®, Besponsa: Uses, Side Effects, Benefits/Risks | Drugs.com, Besponsa | European Medicines Agency, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Besponsa for Acute Lymphoblastic Leukemia Approved by FDA, BESPONSA 1 mg powder for concentrate for solution for , Besponsa: Is this really a viable new treatment for ALL , FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute , FDA approves new treatment for adults with relapsed or .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . Receive a greater number of BESPONSA treatment cycles ; Your doctor should perform liver tests periodically during treatment, and may modify or stop your treatment with BESPONSA. Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.. Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL). Besponsa is used on its own in adults whose cancer has come back or did not respond to previous treatment..
Besponsa can only be obtained with a prescription, and treatment should be given under the supervision of a doctor who has experience in the use of cancer treatments. For further information, see the package leaflet .. BESPONSA ® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Pfizer Inc. announced that the FDA has approved Besponsa (inotuzumab ozogamicin) for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Among patients who proceeded to HSCT after BESPONSA treatment, VOD/SOS was reported in 5/11 (46%) patients who received an HSCT both prior to and after BESPONSA treatment and 13/68 (19%) patients who only received an HSCT after BESPONSA treatment.. August 18, 2017 – B-cell precursor acute lymphoblastic leukemia is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.. The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню